Abstract
Antiangiogenic treatment initiation justifies a clinical and biological pretherapeutic assessment and a close follow-up of side effects according to each drug. Because of potential healing complications, a deadline of 4 weeks after surgery is recommended before starting antiangiogenic treatment. The optimal sequence and the potential role of neo-adjuvant therapies remain to define. In the absence of prospective data, nephrectomy is still recommended in renal cell carcinoma management.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / therapeutic use
-
Bevacizumab
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary
-
Carcinoma, Renal Cell / surgery*
-
Combined Modality Therapy
-
Humans
-
Interferons / therapeutic use
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology
-
Kidney Neoplasms / surgery*
-
Male
-
Middle Aged
-
Nephrectomy*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Bevacizumab
-
Interferons